D. E. Shaw & Co., Inc. Biomea Fusion, Inc. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $443,559 - $1.05 Million	52,994 New	52,994 $769,000
Q2 2023 Aug 14, 2023	SELL	$21.66 - $41.8 $3.08 Million - $5.94 Million	-142,008 Reduced 65.26%	75,579 $1.66 Million
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $928,839 - $4.42 Million	136,594 Added 168.65%	217,587 $6.75 Million
Q4 2022 Feb 14, 2023	BUY	$6.3 - $11.6 $18,339 - $33,767	2,911 Added 3.73%	80,993 $682,000
Q3 2022 Nov 14, 2022	BUY	$9.51 - $13.61 $543,658 - $778,042	57,167 Added 273.33%	78,082 $764,000
Q2 2022 Aug 15, 2022	BUY	$3.0 - $12.03 $62,745 - $251,607	20,915 New	20,915 $251,000
Q1 2022 May 16, 2022	SELL	$4.39 - $9.03 $91,992 - $189,223	-20,955 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.22 - $12.72 $151,295 - $266,547	20,955 New	20,955 $156,000

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $202M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.